It is a broadly described annual report of Square Pharmaceuticals Limited in the year of 2016-2017. The company contributed an amount of Taka. 7,392,467,365 (including Tk. 102,231,588 as contribution as duty/taxes towards machinery & spare parts imports) to National Exchequer as against Taka. 7,301,797,496 in the previous year. During the financial year, The Company’s Gross Revenue Tk. 42,284,675,530. Cost of Goods Sold Tk. 18,274,858,914. Gross Profit Tk. 18,268,281,192. Profit before tax Tk. 12,743,062,576. Net Profit after Tax for the year Tk. 10,647,791,744. The EPS for the year under review is Tk. 11.36, a 3.76% increase over the previous year. EPS calculation took place on the basis of present outstanding 685,945,200 shares of Tk. 10 each.
The Board of Directors proposed and recommended for the declaration of Cash Dividend @35% for the year 2016-2017. The Board also recommended for the declaration of Stock Dividend (Bonus Shares) @7.5%. These financial statements are presented in Bangladesh Taka (Taka/Tk/BDT) which is the company’s functional currency. All financial information presented in Taka has been rounded off to the nearest Taka.
More Annual Report of Square Pharmaceuticals Limited:
- Annual Report 2004 of Square Pharmaceuticals Limited
- Annual Report 2005 of Square Pharmaceuticals Limited
- Annual Report 2006 of Square Pharmaceuticals Limited
- Annual Report 2007 of Square Pharmaceuticals Limited
- Annual Report 2008 of Square Pharmaceuticals Limited
- Annual Report 2009 of Square Pharmaceuticals Limited
- Annual Report 2010 of Square Pharmaceuticals Limited
- Annual Report 2011 of Square Pharmaceuticals Limited
- Annual Report 2012 of Square Pharmaceuticals Limited
- Annual Report 2013 of Square Pharmaceuticals Limited
- Annual Report 2014 of Square Pharmaceuticals Limited
- Annual Report 2015 of Square Pharmaceuticals Limited
- Annual Report 2016 of Square Pharmaceuticals Limited
- Annual Report 2017 of Square Pharmaceuticals Limited
